Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations
Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP,
Mattice M, Fraser R, Young C, Hossain S, Pape T, Payne B,
Radomski C, Donaldson G, Ives E, Cox J, Younghusband HB, Green R,
Duff A, Boltshauser E, Grinspan GA, Dimon JH, Sibley BG,
Andria G, Toscano E, Kerdraon J, Bowsher D, Pimstone SN, Samuels ME,
Sherrington R, Hayden MR.
Xenon Pharmaceuticals Inc.,
3650 Gilmore Way, Burnaby, BC V5G4W8, Canada.
Clin Genet. 2007 Apr;71(4):311-9.
ABSTRACTCongenital indifference to pain (CIP) is a rare condition in which patients have severely impaired pain perception, but are otherwise essentially normal. We identified and collected DNA from individuals from nine families of seven different nationalities in which the affected individuals meet the diagnostic criteria for CIP. Using homozygosity mapping and haplotype sharing methods, we narrowed the CIP locus to chromosome 2q24-q31, a region known to contain a cluster of voltage-gated sodium channel genes. From these prioritized candidate sodium channels, we identified 10 mutations in the SCN9A gene encoding the sodium channel protein Nav1.7. The mutations completely co-segregated with the disease phenotype, and nine of these SCN9A mutations resulted in truncation and loss-of-function of the Nav1.7 channel. These genetic data further support the evidence that Nav1.7 plays an essential role in mediating pain in humans, and that SCN9A mutations identified in multiple different populations underlie CIP.SCN9A
Life without pain?
The neurobiology of pain
Familial indifference to pain
Congenital indifference to pain
Anaesthesia in congenital insensitivity to pain
Anaesthesics and congenital insensitivity to pain
and further reading
The Abolitionist Project
The Hedonistic Imperative
MDMA: Utopian Pharmacology
Critique of Aldous Huxley's Brave New World
The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family